Literature DB >> 28884992

New therapeutic approach by sirolimus for enteropathy treatment in patients with LRBA deficiency.

G Azizi1, H Abolhassani2, R Yazdani3, S Mohammadikhajehdehi4, N Parvaneh4, B Negahdari5, J Mohammadi6, A Aghamohammadi7.   

Abstract

SUMMARY: Purpose. To report the successful use of sirolimus for management of enteropathy in four patients with LPS-responsive beige-like anchor protein (LRBA) deficiency. Methods. Case series. Results. sirolimus therapy led to a complete improvement of symptoms including decrease in frequency and severity of diarrhea, as well as patients' weight gain. No signs of abdominal cramps and anorexia were also detected during the follow up period after treatment. Conclusions. sirolimus with its potential efficacy and immunomodulatory properties may be recommended for the treatment of severe enteropathy refractory to conventional therapy in patients with LRBA deficiency.

Entities:  

Keywords:  LRBA deficiency; Sirolimus; autoimmunity; common variable immune deficiency; enteropathy

Mesh:

Substances:

Year:  2017        PMID: 28884992     DOI: 10.23822/EurAnnACI.1764-1489.22

Source DB:  PubMed          Journal:  Eur Ann Allergy Clin Immunol        ISSN: 1764-1489


  12 in total

Review 1.  The Treatment of Inflammatory Bowel Disease in Patients with Selected Primary Immunodeficiencies.

Authors:  Dror S Shouval; Matthew Kowalik; Scott B Snapper
Journal:  J Clin Immunol       Date:  2018-06-29       Impact factor: 8.317

Review 2.  Monogenic inflammatory bowel disease-genetic variants, functional mechanisms and personalised medicine in clinical practice.

Authors:  Aline Azabdaftari; Kelsey D J Jones; Jochen Kammermeier; Holm H Uhlig
Journal:  Hum Genet       Date:  2022-06-28       Impact factor: 4.132

3.  LRBA is essential for urinary concentration and body water homeostasis.

Authors:  Yu Hara; Fumiaki Ando; Daisuke Oikawa; Koichiro Ichimura; Hideki Yanagawa; Yuriko Sakamaki; Azuma Nanamatsu; Tamami Fujiki; Shuichi Mori; Soichiro Suzuki; Naofumi Yui; Shintaro Mandai; Koichiro Susa; Takayasu Mori; Eisei Sohara; Tatemitsu Rai; Mikiko Takahashi; Sei Sasaki; Hiroyuki Kagechika; Fuminori Tokunaga; Shinichi Uchida
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-21       Impact factor: 12.779

4.  LRBA Deficiency Can Lead to Lethal Colitis That Is Diminished by SHIP1 Agonism.

Authors:  Raki Sudan; Sandra Fernandes; Neetu Srivastava; Chiara Pedicone; Shea T Meyer; John D Chisholm; Robert W Engelman; William G Kerr
Journal:  Front Immunol       Date:  2022-05-04       Impact factor: 8.786

Review 5.  Bacille Calmette-Guerin Complications in Newly Described Primary Immunodeficiency Diseases: 2010-2017.

Authors:  Cristiane de Jesus Nunes-Santos; Sergio D Rosenzweig
Journal:  Front Immunol       Date:  2018-06-22       Impact factor: 7.561

Review 6.  Arthritis in children with LRBA deficiency - case report and literature review.

Authors:  Rotem Semo Oz; Melissa S Tesher
Journal:  Pediatr Rheumatol Online J       Date:  2019-12-17       Impact factor: 3.054

Review 7.  Primary Immune Regulatory Disorders and Targeted Therapies

Authors:  Burcu Kolukısa; Safa Barış
Journal:  Turk J Haematol       Date:  2021-01-14       Impact factor: 1.831

8.  Case Report: Refractory Autoimmune Gastritis Responsive to Abatacept in LRBA Deficiency.

Authors:  Valentina Boz; Erica Valencic; Martina Girardelli; Alessia Pin; Laura Gàmez-Diaz; Alberto Tommasini; Sara Lega; Matteo Bramuzzo
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

9.  Abatacept is effective in Chinese patients with LRBA and CTLA4 deficiency.

Authors:  Lu Yang; Xiuhong Xue; Xuemei Chen; Junfeng Wu; Xi Yang; Li Xu; Xuemei Tang; Mo Wang; Huawei Mao; Xiaodong Zhao
Journal:  Genes Dis       Date:  2020-03-12

10.  Sirolimus is effective in autoimmune lymphoproliferative syndrome-type III: A pedigree case report with homozygous variation PRKCD.

Authors:  Hao Gu; Zhenping Chen; Jie Ma; Jing Wang; Rui Zhang; Runhui Wu; Tianyou Wang
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.